Search Results - "Rosengarten, O"

Safety and dose modification for patients receiving niraparib by Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.

“…Niraparib is a poly(ADP-ribose) polymerase inhibitor approved in the USA and Europe for maintenance treatment of adult patients with recurrent epithelial…”
Get full text

Innovation at life’s end: a moment for hope by Corn, B.W., Rosengarten, O.

Get full text

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions by Karam, A., Ledermann, J.A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R.A., Nam, B.-H., Bacon, M., Ng, C., Pfisterer, J., Bekkers, R.L.M., Casado Herráez, A., Redondo, A., Fujiwara, H., Gleeson, N., Rosengarten, O., Scambia, G., Zhu, J., Okamoto, A., Stuart, G., Ochiai, K.

“…The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo,…”
Get full text

Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines by Bossi, P, Antonuzzo, A, Cherny, N I, Rosengarten, O, Pernot, S, Trippa, F, Schuler, U, Snegovoy, A, Jordan, K, Ripamonti, C I

Get full text

Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer by Evron, E., Ben-David, A.M., Goldberg, H., Fried, G., Kaufman, B., Catane, R., Pfeffer, M.R., Geffen, D.B., Chernobelsky, P., Karni, T., Abdah-Bortnyak, R., Rosengarten, O., Matceyevsky, D., Inbar, M., Kuten, A., Corn, B.W.

“…Women who carry germ-line mutations in BRCA1/2 are at very high risk of developing breast and ovarian cancer. Breast conserving therapy is associated with a…”
Get full text

Safety and dose modification for patients receiving niraparib by Berek, J S, Matulonis, U A, Peen, U, Ghatage, P, Mahner, S, Redondo, A, Lesoin, A, Colombo, N, Vergote, I, Rosengarten, O, Ledermann, J, Pineda, M, Ellard, S, Sehouli, J, Gonzalez-Martin, A, Berton-Rigaud, D, Madry, R, Reinthaller, A, Hazard, S, Guo, W, Mirza, M R

Get full text

Correction to: “Safety and dose modification for patients receiving niraparib” by Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.

Get full text

Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study by Stemmer, S, Steiner, M, Rizel, S, Geffen, D, Nisenbaum, B, Peretz, T, Isaacs, K, Rosengarten, O, Fried, G, Svedman, C, Ben-Baruch, N

Get full text

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score by Stemmer, S, Steiner, M, Rizel, S, Ben-Baruch, N, Soussan-Gutman, L, Rosengarten, O, Geffen, D, Nisenbaum, B, Ryvo, L, Uziely, B, Fried, G, Svedman, C, Rothney, M, Klang, S, Kaufman, B, Isaacs, K, Evron, E, Zidan, J, Shak, S, Liebermann, N

Get full text

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication by Schneeweiss, A., Peretz-Yablonski, T., Nowecki, Z., Merot, J.-L., Pena-Murillo, C., Bachelot, T., Coudert, B., Nowecki, Z., Wardley, A., Puglisi, F., Montemurro, F., Hu, X., Gaafar, R., Li, H., Aktas, B., Tienghi, A., Miles, D., Lux, M., Menjon Beltran, S., Turner, N., Tong, Z., Boer, K., Horvath, Z., Susnjar, S., Matos, E., Garcia Estevez, L., Cruz, M., Bourgeois, H., von Schumann, R., Morales-Vásques, F., Voitko, N., Hicks, J., Barrett-Lee, P., Wheatley, D., Gozy, M., Latini, L., Barnadas Molins, A., Bratos, R., McCarthy, N., Kee, D., Artignan, X., Azribi, F., Jaafar, H., Augereau, P., Müller, V., Evron, E., Cascinu, S., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Kukulska, M., Levitt, N., Panwar, U., Rigg, A., Fein, L., Malik, L., Singer, C., Stoeger, H., Cedeño, M., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Fried, G., Moscetti, L., Siddiqi, N., Arcediano Del Amo, A., McAdam, K., Dunn, G., Taylor, W., Hegg, R., Grosjean, J., Laplaige, P., Christensen, B., Zahm, D.-M., Inbar, M., Bonetti, A., van der Velden, A., van Warmerdam, L., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Joffe, J., Nobre, A., Jiang, J., Padrik, P., Dohollou, N., Prulhiere, K., Ober, A., Alabiso, O., van de Wouw, A.J., Saadein, A., Abdelhafiez, N., Abulkhair, O., Llorente Domenech, R., Gil Raga, M., Rodriguez Sanchez, C., Torrego Garcia, J., Vicente Rubio, E., Jones, A., Alonso, I.

“…The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as…”
Get full text

Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines††FootnotesApproved by the ESMO Guidelines Committee: April 2018 by Bossi, P., Antonuzzo, A., Cherny, N.I., Rosengarten, O., Pernot, S., Trippa, F., Schuler, U., Snegovoy, A., Jordan, K., Ripamonti, C.I.

Get full text

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference by Bookman, M A, Okamoto, A, Stuart, G, Yanaihara, N, Aoki, D, Bacon, M, Fujiwara, K, González-Martín, A, Harter, P, Kim, J W, Ledermann, J, Pujade-Lauraine, E, Quinn, M, Ochiai, K

“…The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided…”
Get full text

Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years by Stemmer, SM, Rizel, S, Steiner, M, Geffen, DB, Soussan-Gutman, L, Bareket-Samish, A, McCullough, D, Svedman, C, Nisenbaum, B, Ryvo, L, Peretz, T, Fried, G, Rosengarten, O, Liebermann, N, Ben Baruch, N

“…Abstract Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in…”
Get full text

P249 - Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization by Stemmer, S.M., Leviov, M., Tokar, M., Ben-Baruch, N., Uziely, B., Fried, G., Rosengarten, O., Itay, A., Nisenbaum, B., Shak, S.

Get full text

Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization by Stemmer, S.M., Leviov, M., Tokar, M., Ben-Baruch, N., Uziely, B., Fried, G., Rosengarten, O., Itay, A., Nisenbaum, B., Shak, S.

Get full text

First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result by Stemmer, S.M., Steiner, M., Rizel, S., Geffen, D., Nisenbaum, B., Peretz, T., Soussan-Gutman, L., Bareket-Samish, A., Isaacs, K., Rosengarten, O., Fried, G., Svedman, C., Shak, S., Liebermann, N., Ben-Baruch, N.

Get full text

P251 - Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study by Stemmer, S., Steiner, M., Rizel, S., Geffen, D., Nisenbaum, B., Peretz, T., Isaacs, K., Rosengarten, O., Fried, G., Svedman, C., Ben-Baruch, N.

Get full text

gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) by Mirza, M.R., Monk, B.J., Oza, A., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J., Lorusso, D., Vergote, I.B., Rosengarten, O., Berek, J., Herrstedt, J., Tinker, A.V., Dubois, A., Martin, A. Gonzalez, Follana, P., Benigno, B., Rimel, B.J., Agarwal, S., Matulonis, U.

Get full text

Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98 by Stemmer, SM, Steiner, M, Rizel, S, Soussan-Gutman, L, Geffen, DB, Nisenbaum, B, Ben-Baruch, N, Isaacs, K, Fried, G, Rosengarten, O, Uziely, B, Svedman, C, Rothney, M, Klang, SH, Ryvo, L, Kaufman, B, Evron, E, Zidan, J, Shak, S, Liebermann, N

“…Abstract Background: The 21-Gene Recurrence Score® Assay (Oncotype DX®) has been validated as a prognostic and predictive tool in estrogen receptor (ER)+…”
Get full text

Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines by Bossi, P, Antonuzzo, A, Cherny, N I, Rosengarten, O, Pernot, S, Trippa, F, Schuler, U, Snegovoy, A, Jordan, K, Ripamonti, C I

Get full text